- Biotech Cynata Therapeutics has announced positive efficacy data from a Cymerus mesenchymal stem cell study in rodents with IPF
- IPF, idiopathic pulmonary fibrosis, is a type of lung disease that results in the scarring of the lungs for an unknown reason
- As the scarring gets worse, it becomes harder to take in a deep breath as the lungs cannot take in enough oxygen
- Compared to a placebo, Cynata’s MSC treatment led to significant improvements in the lung compliance, lung inflammation, and airway resistance
- Then the initial phase of this study found that the control animals suffered a 40 per cent loss of lung compliance after a cancer medicine wasadministered
- Cynata is up a slight 1.72 per cent and shares are trading for 88.5 cents each
